Sun Pharma Advanced Research vs Nifty 50

Sun Pharma Advanced Research Company vs Nifty 50 is a comparison that looks different depending on the time frame chosen. Sun Pharma Advanced Research Company trades on the NSE under the symbol SPARC, and its 1M return of -2.87% compares with the Nifty 50's -1.44% over the same period.

The Sun Pharma Advanced Research Company vs Nifty 50 comparison matters because Sun Pharma Advanced Research Company is a single stock exposed to its own sector and company-specific developments, while the Nifty 50 spreads risk across 50 large companies. This article lines up Sun Pharma Advanced Research Company share price performance against the Nifty 50 across 1 month, 3 months, 6 months, 1 year, 3 years, 5 years, using NSE closing data.

Click Here – Get Free Investment Predictions

Sun Pharma Advanced Research Company vs Nifty 50: Performance at a Glance

The table below sets out Sun Pharma Advanced Research Company vs Nifty 50 performance across the available time frames, measured from NSE closing prices up to 2 September 2026.

Time Frame	Sun Pharma Advanced Research Company Return	Nifty 50 Return	Difference
1 Month	-2.87%	-1.44%	-1.42% pp
3 Months	+2.0%	+2.78%	-0.77% pp
6 Months	+59.07%	-3.35%	+62.42% pp
1 Year	+41.21%	-2.41%	+43.62% pp
3 Years	-19.99%	+23.65%	-43.64% pp
5 Years	-33.19% (Sun Pharma Advanced Research Company)	+40.73% (Nifty 50)	-73.92% pp

On the Sun Pharma Advanced Research Company vs Nifty 50 scorecard, Sun Pharma Advanced Research Company has stayed ahead of the index over the most recent one-year window. Over the longer term the index has pulled ahead, a reminder that short-term outperformance does not always hold up over multi-year horizons.

Check the Univest Screener for live Sun Pharma Advanced Research Company and Nifty 50 data

Why the Sun Pharma Advanced Research Company vs Nifty 50 Gap Exists

Sun Pharma Advanced Research Company's stock can move quite differently from the Nifty 50 because it carries concentrated exposure to its own sector and business cycle, unlike the index which blends 50 companies across banking, IT, energy and consumer sectors. This is the main driver of the gap seen in the Sun Pharma Advanced Research Company vs Nifty 50 return table above.

A second factor behind the Sun Pharma Advanced Research Company vs Nifty 50 divergence is valuation and trading liquidity. Company-specific news, quarterly results and sector sentiment can move Sun Pharma Advanced Research Company's price sharply in either direction over short periods, while the Nifty 50's return reflects the blended earnings trajectory of its constituents and is far less exposed to any single stock's swings.

Download the Univest iOS App or Univest Android App to track Sun Pharma Advanced Research Company and Nifty 50 live on the go.

Sun Pharma Advanced Research Company vs Nifty 50: Has Sun Pharma Advanced Research Company Beaten the Benchmark?

Sun Pharma Advanced Research Company has beaten the Nifty 50 over the past year, gaining +41.21% against the index's -2.41% over the same period. Over the longer term the index has closed some of that gap.

Risks of the Sun Pharma Advanced Research Company vs Nifty 50 Comparison

Reading too much into a Sun Pharma Advanced Research Company vs Nifty 50 comparison has real limitations that investors should weigh before drawing conclusions. Sun Pharma Advanced Research Company carries concentrated business and sector risk that a diversified index does not, and its trading volumes and price swings can differ meaningfully from the Nifty 50's more liquid, blended profile. A stock's 52-week range of Rs 108.00 to Rs 289.00 also shows the kind of volatility that a single-stock investment carries relative to a broad index.

Conclusion

Sun Pharma Advanced Research Company vs Nifty 50 highlights how a single stock's return path can differ from a diversified benchmark over different time horizons. Investors weighing the Sun Pharma Advanced Research Company vs Nifty 50 record should factor in Sun Pharma Advanced Research Company's volatility, liquidity and sector concentration alongside its return history, and consult a SEBI-registered advisor before making an allocation decision.

Has Sun Pharma Advanced Research Company outperformed the Nifty 50 in the last year?

Ans. Yes. Sun Pharma Advanced Research Company gained +41.21% over the past year while the Nifty 50 returned -2.41% over the same period, based on NSE closing prices to 2 September 2026.

How does Sun Pharma Advanced Research Company vs Nifty 50 look over 5 years?

Ans. Over five years Sun Pharma Advanced Research Company has returned -33.19% compared with the Nifty 50's +40.73%, so in the Sun Pharma Advanced Research Company vs Nifty 50 comparison the index has been ahead over this longer horizon.

What is the Sun Pharma Advanced Research Company share price today compared to Nifty 50?

Ans. Sun Pharma Advanced Research Company share price stood at Rs 200.30 on NSE, while the Nifty 50 traded at 24,031.60 based on the same closing data window.

What is the 52-week high and low of Sun Pharma Advanced Research Company?

Ans. Sun Pharma Advanced Research Company's 52-week high is Rs 289.00 and its 52-week low is Rs 108.00, based on NSE data.

Why does Sun Pharma Advanced Research Company show bigger price swings than the Nifty 50?

Ans. Sun Pharma Advanced Research Company carries concentrated exposure to its own sector and business cycle, while the Nifty 50 spreads risk across 50 large companies, so company-specific news moves Sun Pharma Advanced Research Company's price more sharply than the diversified index, a key reason the Sun Pharma Advanced Research Company vs Nifty 50 return gap varies across time frames.

Is Sun Pharma Advanced Research Company a good long-term investment compared to a Nifty 50 index fund?

Ans. Sun Pharma Advanced Research Company's suitability depends on an investor's risk appetite, since single-stock exposure carries higher concentration risk than a diversified Nifty 50 index fund; long-term investors should weigh the Sun Pharma Advanced Research Company vs Nifty 50 return history alongside the company's fundamentals and consult a SEBI-registered advisor.